Literature DB >> 32592442

30-day mortality following palliative radiotherapy.

Mollie Kain1,2, Hayley Bennett1, Ma Yi3, Bridget Robinson1,4, Melissa James1,4.   

Abstract

INTRODUCTION: Patients dying a short time after receiving palliative radiation are unlikely to have received benefit and may experience harm. To monitor the potential for avoidable harm, 30-day mortality following palliative radiation has been recommended for use as a quality indicator and the Royal College of Radiologist have recommended a rate of lower than 20%. At the Canterbury Regional Cancer and Haematology Service in Christchurch, New Zealand (CRCHS), we investigated 30-day mortality and evaluated the prognostic value of the TEACHH model in our population.
METHODS: Palliative treatments from two, two-year periods (2012/2013 and 2016/2017) were retrospectively reviewed. We analysed 30-day mortality and several influencing variables. Patients were divided into three groups using the TEACHH model (type of cancer, performance status, age, prior palliative chemotherapy, prior hospitalizations and hepatic metastases).
RESULTS: There were 1744 patients; 30-day mortality was 10% and was higher in patients with lung cancer (17% vs. 8% in non-lung cancer patients, P < 0.0001), patients having less than five fractions (13% vs. 9%, P: 0.0199) and patients in TEACHH group B/C (21% in C, 11% in B and 2% in group A, P < 0.0001). The majority of treatments (84%) used five fractions or less.
CONCLUSIONS: The mortality rate is within the suggested quality indicator, and the decreasing mortality with increasing fractionation demonstrates suitable selection of patients for longer treatment regimens. The TEACHH model can be used to increase precision in estimating prognosis, identifying patients who should not receive treatment and conversely identifying those for whom a prolonged fractionation schedule may be appropriate.
© 2020 The Royal Australian and New Zealand College of Radiologists.

Entities:  

Keywords:  30-day mortality; TEACHH; palliative radiotherapy

Mesh:

Year:  2020        PMID: 32592442     DOI: 10.1111/1754-9485.13073

Source DB:  PubMed          Journal:  J Med Imaging Radiat Oncol        ISSN: 1754-9477            Impact factor:   1.735


  3 in total

1.  30-Day Mortality Following Palliative Radiotherapy.

Authors:  Miriam Vázquez; Manuel Altabas; Diana C Moreno; Abraham A Geng; Santiago Pérez-Hoyos; Jordi Giralt
Journal:  Front Oncol       Date:  2021-04-23       Impact factor: 6.244

2.  Dual Use of the METSSS Model Predicting Survival After Palliative Radiotherapy: An Exploratory Analysis.

Authors:  Carsten Nieder; Bård Mannsåker; Rosalba Yobuta
Journal:  Cureus       Date:  2022-01-13

3.  Prognostication in palliative radiotherapy-ProPaRT: Accuracy of prognostic scores.

Authors:  Marco Maltoni; Emanuela Scarpi; Monia Dall'Agata; Simona Micheletti; Maria Caterina Pallotti; Martina Pieri; Marianna Ricci; Antonino Romeo; Maria Valentina Tenti; Luca Tontini; Romina Rossi
Journal:  Front Oncol       Date:  2022-08-16       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.